Journal Article

Clinical manifestations of AB‐amyloidosis: effects of biocompatibility and flux

Helmut Schiffl, Rainald Fischer, Susanne M. Lang and Eugen Mangel

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 15, issue 6, pages 840-845
Published in print June 2000 | ISSN: 0931-0509
Published online June 2000 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/15.6.840
Clinical manifestations of AB‐amyloidosis: effects of biocompatibility and flux

Show Summary Details

Preview

Background. Highly permeable biocompatible dialysis membranes may postpone the development of AB‐amyloidosis, but the relative contribution of enhanced flux or reduced inflammation by highly biocompatible membranes and sterile dialysis fluid remains unknown.

Methods. In this retrospective investigation, 89 patients with end‐stage renal disease maintained on regular haemodialysis for at least 10 years and treated with one type of dialysis membrane exclusively were selected for analysis. They were divided into three groups: low‐flux, bioincompatible cellulose (I), low‐flux, intermediately biocompatible polysulphone or PMMA (II), or high‐flux, highly biocompatible polysulphone or AN69 (III). In addition, the patients were analysed according to the microbiological quality of the dialysis fluid, which had been tested regularly and was classified either as standard or as intermittently contaminated. The clinical manifestations indicative of AB‐amyloidosis, namely, carpal tunnel syndrome, arthropathy and bone cysts, were diagnosed after recruitment.

Results. Clinical symptoms were most pronounced in group I, intermediate in group II, and lowest in group III. Patients treated with intermittently contaminated dialysis fluid showed a higher prevalence of AB‐amyloidosis than patients with less contaminated dialysis fluid. Logistic regression analysis demonstrated that the flux characteristics of the dialyser and the microbiological quality of the dialysis fluid as well as the biocompatibility of the dialyser were independent determinants of AB‐amyloidosis.

Conclusion. It would be prudent clinical practice to employ high‐flux biocompatible membranes in conjunction with ultrapure dialysis fluid for the treatment of end‐stage renal disease patients who need to remain on long‐term haemodialysis.

Keywords: AB‐amyloidosis; biocompatibility; dialysis fluid; haemodialysis membrane

Journal Article.  4087 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.